J2J-MC-JZLH EMBER-4: A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer with an Increased Risk of Recurrence,
Role: Investigator,
Eli Lilly & Co.,
(06/2024 - 06/2025)
Status: Approved
A Phase 1b/2 Study Assessing the Safety and Efficacy of Evexomostat (SDX-7320) in Combination with a PI3K Pathway Inhibitor plus Fulvestrant in Postmenopausal Women with Advanced Breast Cancer and PII3K Pathway Alterations Who Have Progressed on or Following Endocrine Therapy plus a CDK4/6 Inhibitor,
Role: Investigator,
SynDevRx, Inc.,
(02/2025 - 02/2026)
Status: Approved
Internal
Investigator Initiated: A phase II trial of preoperative chemotherapy (with gemcitabine and nab-paclitaxel) and stereotactic body radiotherapy followed by surgery and chemotherapy in patients with resectable pancreatic adenocarcinoma,
Role: Investigator,
LLU Dept. of Surgery,
(09/2024 - 09/2025)
Status: Approved